LRP8 · Western blot design guide

LRP8 Western Blot Planning Guide

Plan a LRP8 Western blot around the catalog-observed 105.6 kDa band, image-backed A03444-2 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for LRP8 (LRP8): expected band 105.6 kDa, antibody A03444-2, and guide-derived SDS-PAGE protocol steps
LRP8 Western blot protocol sheet — expected band 105.6 kDa, antibody A03444-2, controls and PMC citations. Open the full LRP8 WB guide →

LRP8 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 105.6 kDa
Observed band Not reported — verify product WB image
Gel 8-10%
Positive control ⓘ Testis
Negative control ⓘ Appendix
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 105.6 kDa
ⓘ Localization Cell membrane / Secreted
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated LRP8 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateTestis
Gel %8-10%
Load20-30 µg total protein per lane
TransferWet/tank, extended transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA03444-2 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected LRP8 Western Blot Band Size?

Use the product-observed 105.6 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
105.6 kDaMatches the authoritative product WB observation.
105.6 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected LRP8 appearancePlan around 105.6 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band105.6 kDa; use this as the primary experimental expectation.
Calculated mass105.6 kDa from UniProt Q14114; retain as context.
Gel selection8-10%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A03444-2.
Why is my band missing or off?
SituationLikely causeNext action
105.6 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for LRP8 Western blot

🧪Use Testis as the first positive-control candidate and Appendix as the HPA Not detected negative candidate.
Positive control: Testis (High)
Negative control: Appendix (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for LRP8

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Testis Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Appendix Reported tissue cells Not detected Protein (HPA) HPA →
Bone marrow Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced LRP8 Western Blot Tips

Deeper troubleshooting and optimisation questions for LRP8, answered from its protein features.

Which band should guide the blot?
Use 105.6 kDa, the observation attached to the authoritative A03444-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 105.6 kDa expectation.
Which positive control should I start with?
Start with Testis, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Appendix as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for LRP8 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A03444-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

LRP8 Western Blot Reagents

Human/Mouse/Rat-reactive LRP8 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for LRP8 using A03444-2; observed band 105.6 kDa
Anti-ApoER2/LRP8 Antibody Picoband®
Cat # A03444-2

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt Q14114
  2. Human Protein Atlas — LRP8
  3. A03444-2 product record
  4. PMC12412626 — LRP8 Regulates Lipid Metabolism to Stimulate Malignant Progression and Cisplatin Resistance in Bladder Cancer (The Kaohsiung journal of medical sciences, 2025)
  5. PMC11954824 — Enhanced LRP8 expression induced by Helicobacter pylori drives gastric cancer progression by facilitating β-Catenin nuclear translocation (Journal of advanced research, 2025)
  6. PMC10405063 — LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma (EMBO molecular medicine, 2023)